Fumito Yamazaki

Fumito Yamazaki

Auto-generated profile, based on publicly available information

Fumito Yamazaki

Department of Pediatrics Keio University School of Medicine Tokyo Japan

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2021 in Cancer Science
Verified
Journal Article
Open access
PDF file
MFMichinori Funato
Michinori Funato
YTYukiko Tsunematsu
Yukiko Tsunematsu
FYFumito Yamazaki
Fumito Yamazaki
CTChieko Tamura
Chieko Tamura
TKTadashi Kumamoto
Tadashi Kumamoto
KTKazuo Tamura
Kazuo Tamura
Li‐Fraumeni syndrome (LFS) is a hereditary cancer predisposition syndrome, and the majority of patients with LFS have been identified with germline variants in the p53 tumor suppressor (TP53) gene. In the past three decades, considerable case reports of TP53 germline variants have been published in Japan. To the best of our knowledge, there have been no large‐scale studies of Japanese patients with LFS. In this study, we aimed to identify Japanese patients with TP53 germline variants and to reveal the characteristics of LFS in Japan. We collected reported cases by reviewing the medical literature and cases diagnosed at the institutions of the authors. We identified 68 individuals from 48 families with TP53 germline pathogenic or likely pathogenic variants. Of the 48 families, 35 (72.9%) had missense variants, most of which were located within the DNA‐binding loop. A total of 128 tumors were identified in the 68 affected individuals. The 128 tumor sites were as follows: breast, 25; bones, 16; brain, 12; hematological, 11; soft tissues, 10; stomach, 10; lung, 10; colorectum, 10; adrenal gland, 9; liver, 4; and others, 11. Unique phenotype patterns of LFS were shown in Japan in comparison with those in a large national LFS cohort study in France. Above all, a higher frequency of patients with stomach cancer was observed in Japanese TP53 germline variant carriers. These results may provide useful information for the clinical management of LFS in Japan.

31 March 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
FYFumito Yamazaki
Fumito Yamazaki
KYKai Yamasaki
Kai Yamasaki
CKChikako Kiyotani
Chikako Kiyotani
YHYoshiko Hashii
Yoshiko Hashii
YSYoko Shioda
Yoko Shioda
KMKimikazu Matsumoto
Kimikazu Matsumoto

1 July 2023 in JCO Precision Oncology
Verified
Journal Article
Closed access
KTKayoko Tao
Kayoko Tao
FYFumito Yamazaki
Fumito Yamazaki
TKTakashi Kubo
Takashi Kubo
KSKuniko Sunami
Kuniko Sunami
TKTadashi Kumamoto
Tadashi Kumamoto
COChitose Ogawa
Chitose Ogawa
PURPOSE: This single-center, prospective molecular profiling study characterizes genomic alterations and identifies therapeutic targets in advanced pediatric solid tumors. METHODS: As part of the TOP-GEAR (Trial of Onco-Panel for Gene profiling to Estimate both Adverse events and Response by cancer treatment) project at the National Cancer Center (NCC), Japan, we enrolled pediatric patients with a refractory or recurrent disease during August 2016-December 2021 and performed genomic analysis of matched tumors and blood using originally developed cancer gene panels, NCC Oncopanel (ver. 4.0) and NCC Oncopanel Ped (ver. 1.0). RESULTS: Of 142 patients (age, 1-28 years) enrolled, 128 (90%) were evaluable for genomic analysis; 76 (59%) patients harbored at least one reportable somatic or germline alteration. The tumor samples were collected during the initial diagnosis in 65 (51%) patients, after treatment initiation in 11 (9%) patients, and upon either disease progression or relapse in 52 (41%) patients. The leading altered gene was TP53, followed by MYCN, MYC, CDKN2A, and CDK4. The commonly affected molecular processes were transcription, cell-cycle regulation, epigenetic modifiers, and RAS/mitogen-activated protein kinase signaling. Twelve (9%) patients carried pathogenic germline variants in cancer-predisposing genes. Potentially actionable findings were identified in 40 (31%) patients; to date, 13 (10%) patients have received the recommended therapy on the basis of their genomic profiles. Although four patients had access to targeted therapy through clinical trials, the agents were used in nine patients in an off-label setting. CONCLUSION: The implementation of genomic medicine has furthered our understanding of tumor biology and provided new therapeutic strategies. However, the paucity of proposed agents limits the full potential of actionability, emphasizing the significance of facilitating access to targeted cancer therapies.

10 August 2023 in Cancer Reports
Verified
Journal Article
Open access
KKKento Kawata
Kento Kawata
HSHaruko Shima
Haruko Shima
MSMasayoshi Shinjoh
Masayoshi Shinjoh
FYFumito Yamazaki
Fumito Yamazaki
TKTakumi Kurosawa
Takumi Kurosawa
HSHiroyuki Shimada
Hiroyuki Shimada
Background: CD19‐targeted chimeric antigen receptor (CAR)‐T cell therapy involves administration of patient‐derived T cells that target B cells, resulting in B‐cell depletion and aplasia. In immunity against Pneumocystis jirovecii (Pj), CD4+ T cells and, more recently, B cells, are generally considered important. Antigen presentation by B cells to CD4+ T cells is particularly important. Trimethoprim‐sulfamethoxazole (TMP/SMX) for Pj pneumonia (PJP) prophylaxis is generally discontinued when the CD4+ T‐cell count is >200/μL. Here we report the first case, to our knowledge, of PJP in a patient with a CD4+ T cell count of >200/μL after CAR‐T cell therapy.Case: A 14‐year‐old girl developed hemophagocytic lymphohistiocytosis (HLH) after cord blood transplantation (CBT) for relapsed precursor B‐cell acute lymphoblastic leukemia (B‐ALL). Twenty‐one months after CBT, she was diagnosed with combined second relapse in the bone marrow and central nervous system. The patient was treated with CD19‐targeted CAR‐T cell therapy for the relapse. After CAR‐T cell therapy, the patient remained in remission and continued to receive TMP/SMX for PJP prophylaxis. Seven months after CAR‐T cell therapy, CD4+ T cells recovered and TMP/SMX was discontinued. The B‐cell aplasia persisted. Ten months after CAR‐T cell therapy, the patient developed PJP. The patient was also considered to have macrophage hyperactivation at the onset of PJP. Treatment with immunoglobulin, TMP/SMX, and prednisolone was initiated, and the patient's symptoms rapidly ameliorated.Conclusion: The patient in the present case developed PJP despite a CD4+ T‐cell count of >200/μL after CAR‐T cell therapy, probably because of inadequate CD4+ T‐cell activation caused by B‐cell depletion after CAR‐T cell therapy and repeated abnormal macrophage immune responses after CBT. It is important to determine the duration of TMP/SMX for prophylaxis after CAR‐T cell therapy according to each case, as well as the CD4+ T‐cell count.

19 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
YNYoshiko Nakano
Yoshiko Nakano
YTYukiko Tsunematsu
Yukiko Tsunematsu
FYFumito Yamazaki
Fumito Yamazaki
AMAtsushi Manabe
Atsushi Manabe
ANAkira Nakagawara
Akira Nakagawara
TKTadashi Kumamoto
Tadashi Kumamoto

9 June 2026 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
KFKyohei Furusawa
Kyohei Furusawa
JIJumpei Ito
Jumpei Ito
YIYayoi Ichikawa
Yayoi Ichikawa
FYFumito Yamazaki
Fumito Yamazaki
RNRisako Narukama
Risako Narukama
HSHiroyuki Shimada
Hiroyuki Shimada